Takeda strikes again, Shire board recommends $64bn offer

By Flora Southey

- Last updated on GMT

GettyImages/Tero Vesalainen
GettyImages/Tero Vesalainen
Having rejected four of Takeda’s bids, Shire says it is willing to recommend the Japanese firm’s latest acquisition offer to its shareholders.

Yesterday Shire announced​ receipt of a revised acquisition proposal from Takeda Pharmaceutical Company, equivalent to a value of approximately £46bn ($64bn).

Shire’s board says it is willing to recommend the offer to its shareholders and will extend the deadline until 5pm (GMT) on May 8, 2018.

Shire had previously rejected​ Takeda’s acquisition proposals, saying the offers "undervalue" its pipeline and potential for growth.

But Takeda’s offers have steadily increased over the past month and the latest bid is 4% above the prior cash offer, investment banking firm Jefferies published​ this morning.

The cash component of the current proposal is largely unchanged.

“If accepted, SHPG [Shire] shareholders will become ~50% owners in the NewCo. That said, are SHPG shareholders willing to accept an offer that is in effect 44% cash and 56% equity?”​ the analysts added.

Neither Takeda nor Shire responded to a request for comment before the time of publishing.

 

 

Related topics Bio Developments Facilities

Related news

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars